DISEASE & TREATMENT SETTING

Childhood Thyroid Cancer

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Thyroid Cancer in children and adolescents

Source population: pediatric
Disease extent: Not part of this definition
Treatment line: Not part of this definition
Stage: Not part of this definition
Resectability: Not part of this definition

Biomarkers, prior therapy and derivation

molecular
prior therapy
derivation status: source-attested
derivation note: Derived from NCI topic(s): Childhood Thyroid Cancer. Strongest NCIt resolution: exact. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
source wording: Source null

12 more-specific settings

Study evidence for this setting

Find a linked studyHow it was found

0 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.

Indication-specific source history

Dated source events, not confirmation of current approval for every use of a drug.

2020-05-08 · Retevmo (selpercatinib) · accelerated approval

release id: clinical-indications-draft-1
disease state id: ds-thyroid-cancer-pediatric
event id: fda-71a184400881623a
event date: 2020-05-08
event kind: accelerated-approval
drug or regimen: Retevmo (selpercatinib)
source indication text: Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy *
match phrase: thyroid cancer
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-34303ef4a0f5d9da66ed
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2020-05-08 · Retevmo (selpercatinib) · accelerated approval

release id: clinical-indications-draft-1
disease state id: ds-thyroid-cancer-pediatric
event id: fda-e073a86346d84dba
event date: 2020-05-08
event kind: accelerated-approval
drug or regimen: Retevmo (selpercatinib)
source indication text: Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) *
match phrase: thyroid cancer
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-72ab3fa819df036d6fb3
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2020-12-01 · Gavreto (pralsetinib) · accelerated approval

release id: clinical-indications-draft-1
disease state id: ds-thyroid-cancer-pediatric
event id: fda-00745d46cd62c1e5
event date: 2020-12-01
event kind: accelerated-approval
drug or regimen: Gavreto (pralsetinib)
source indication text: Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)
match phrase: thyroid cancer
match status: candidate
status category: ongoing
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-b86c12dadbbbf05b6c82
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2020-12-01 · Gavreto (pralsetinib) · accelerated approval

release id: clinical-indications-draft-1
disease state id: ds-thyroid-cancer-pediatric
event id: fda-1c569388cc164e61
event date: 2020-12-01
event kind: accelerated-approval
drug or regimen: Gavreto (pralsetinib)
source indication text: Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy
match phrase: thyroid cancer
match status: candidate
status category: withdrawn
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-aa53a9ab79697a07fa63
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2023-07-20 · Gavreto (pralsetinib) · withdrawal

release id: clinical-indications-draft-1
disease state id: ds-thyroid-cancer-pediatric
event id: fda-cc1d19d9ed25e7bb
event date: 2023-07-20
event kind: withdrawal
drug or regimen: Gavreto (pralsetinib)
source indication text: Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy
match phrase: thyroid cancer
match status: candidate
status category: withdrawn
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-aa53a9ab79697a07fa63
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2024-06-12 · Retevmo (selpercatinib) · traditional approval

release id: clinical-indications-draft-1
disease state id: ds-thyroid-cancer-pediatric
event id: fda-793cb8998d22b54f
event date: 2024-06-12
event kind: traditional-approval
drug or regimen: Retevmo (selpercatinib)
source indication text: Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) *
match phrase: thyroid cancer
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-72ab3fa819df036d6fb3
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2024-09-27 · Retevmo (selpercatinib) · traditional approval

release id: clinical-indications-draft-1
disease state id: ds-thyroid-cancer-pediatric
event id: fda-21c5c4e24dbcccf8
event date: 2024-09-27
event kind: traditional-approval
drug or regimen: Retevmo (selpercatinib)
source indication text: Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy *
match phrase: thyroid cancer
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-34303ef4a0f5d9da66ed
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

Source relationships and population-mapping limitations

bindings

release id
clinical-indications-draft-1
disease state id
ds-thyroid-cancer-pediatric
binding id
ncit-C4815
source collection
ncit-concept
source key
C4815
source excerpt
Source null
match status
exact
match note
Source null
recorded at
2026-09-10T00:00:00Z

mappings

Download this complete draft source relationship record →

Preserved source evidence · Not medical advice